Burton, Dennis R.
Dennis R. Burton researcher
Burton, Dennis R., 1931-....
VIAF ID: 30433945 (Personal)
Permalink: http://viaf.org/viaf/30433945
Preferred Forms
- 100 1 _ ‡a Burton, Dennis R
- 100 1 _ ‡a Burton, Dennis R
- 100 1 _ ‡a Burton, Dennis R
-
-
- 100 1 _ ‡a Burton, Dennis R.
-
-
-
- 100 1 _ ‡a Burton, Dennis R.
-
-
-
- 100 1 _ ‡a Burton, Dennis R., ‡d 1931-....
- 100 0 _ ‡a Dennis R. Burton ‡c researcher
4xx's: Alternate Name Forms (5)
Works
Title | Sources |
---|---|
Antibodies in viral infection, 2001: | |
Fondements de l'immunologie | |
Hidden Lineage Complexity of Glycan-Dependent HIV-1 Broadly Neutralizing Antibodies Uncovered by Digital Panning and Native-Like gp140 Trimer | |
Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo | |
An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability | |
HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen | |
HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds | |
HIV-1 neutralization: mechanisms and relevance to vaccine design | |
HIV-1 vaccine design through minimizing envelope metastability | |
HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage | |
HIV: Immune memory downloaded. | |
HIV vaccine design: insights from live attenuated SIV vaccines | |
HIV vaccine research: the way forward | |
Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies | |
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus | |
Human recombinant antimannan immunoglobulin G1 antibody confers resistance to hematogenously disseminated candidiasis in mice | |
Hyperglycosylated Mutants of Human Immunodeficiency Virus (HIV) Type 1 Monomeric gp120 as Novel Antigens for HIV Vaccine Design | |
Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody | |
Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes | |
Identification of peptides from human pathogens able to cross-activate an HIV-1-gag-specific CD4+ T cell clone | |
IDEPI: rapid prediction of HIV-1 antibody epitopes and other phenotypic features from sequence data using a flexible machine learning platform | |
Immune responses and HIV: a little order from the chaos | |
Immune tolerance negatively regulates B cells in knock-in mice expressing broadly neutralizing HIV antibody 4E10 | |
Immunochemical engineering of cell surfaces to generate virus resistance | |
Immunofocusing: antigen engineering to promote the induction of HIV-neutralizing antibodies | |
Immunology. Sugar determines antibody activity | |
Immunology. Two-in-one designer antibodies. | |
Induction of Transient Virus Replication Facilitates Antigen-Independent Isolation of SIV-Specific Monoclonal Antibodies | |
Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes | |
Inhibition of HIV-1 infectivity and epithelial cell transfer by human monoclonal IgG and IgA antibodies carrying the b12 V region | |
Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120. | |
Inhibition of mammalian glycan biosynthesis produces non-self antigens for a broadly neutralising, HIV-1 specific antibody. | |
Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak | |
Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody | |
Live simian immunodeficiency virus vaccine correlate of protection: local antibody production and concentration on the path of virus entry | |
Macaque long-term nonprogressors resist superinfection with multiple CD8+ T cell escape variants of simian immunodeficiency virus | |
Macaques vaccinated with simian immunodeficiency virus SIVmac239Delta nef delay acquisition and control replication after repeated low-dose heterologous SIV challenge | |
Major histocompatibility complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute-phase cytotoxic-T-lymphocyte responses | |
Making autoantibodies safe | |
Manipulating the selection forces during affinity maturation to generate cross-reactive HIV antibodies | |
Mapping Neutralizing Antibody Epitope Specificities to an HIV Env Trimer in Immunized and in Infected Rhesus Macaques | |
Mapping Polyclonal Antibody Responses in Non-human Primates Vaccinated with HIV Env Trimer Subunit Vaccines | |
Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates | |
Measuring prions causing bovine spongiform encephalopathy or chronic wasting disease by immunoassays and transgenic mice | |
Mechanisms of escape from the PGT128 family of anti-HIV broadly neutralizing antibodies | |
Metal ions as nuclear magnetic resonance probes in biology | |
Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design. | |
Mining the antibodyome for HIV-1-neutralizing antibodies with next-generation sequencing and phylogenetic pairing of heavy/light chains | |
Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions | |
Modular synthesis of N-glycans and arrays for the hetero-ligand binding analysis of HIV antibodies | |
Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120. | |
Motif-grafted antibodies containing the replicative interface of cellular PrP are specific for PrPSc | |
An MPER antibody neutralizes HIV-1 using germline features shared among donors | |
Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies | |
Multiplex PCR method for MinION and Illumina sequencing of Zika and other virus genomes directly from clinical samples | |
Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity | |
Myeonyeokhak | |
N-Butyldeoxynojirimycin is a broadly effective anti-HIV therapy significantly enhanced by targeted liposome delivery | |
n2001014483 | |
Natural resistance of human immunodeficiency virus type 1 to the CD4bs antibody b12 conferred by a glycan and an arginine residue close to the CD4 binding loop | |
Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. | |
Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas | |
Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity | |
A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity | |
A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcγ receptors to define the role of effector functions in protection against HIV. | |
A peptide inhibitor of HIV-1 neutralizing antibody 2G12 is not a structural mimic of the natural carbohydrate epitope on gp120 | |
Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque | |
Rapid elicitation of broadly neutralizing antibodies to HIV by immunization in cows. | |
A recombinant human monoclonal antibody to human metapneumovirus fusion protein that neutralizes virus in vitro and is effective therapeutically in vivo | |
A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples | |
Roitt's essential immunology | |
A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies | |
Vaccination strategies against highly variable pathogens | |
A welcome burst of human antibodies. | |
면역학 |